Rockman H A, Wachhorst S P, Mao L, Ross J
Department of Medicine, University of California San Diego School of Medicine, La Jolla 92093.
Am J Physiol. 1994 Jun;266(6 Pt 2):H2468-75. doi: 10.1152/ajpheart.1994.266.6.H2468.
There is increasing evidence that the renin-angiotensin system may play a important role in cardiac hypertrophy. To assess the role of angiotensin II in the induction of cardiac hypertrophy, three groups of adult mice were subjected to left ventricular pressure overload by transverse aortic constriction (TAC). For the next 7 days the groups received either the specific angiotensin II subtype 1 receptor (AT1) antagonist (losartan, 1.05 g/l; n = 17), an angiotensin enzyme inhibitor (captopril, 2 g/l; n = 17), or no treatment (n = 22) administered in the drinking water and compared with three similarly treated sham-operated groups (n = 7 each). TAC resulted in a significant increase in heart weight-to-body weight ratio (0.634 +/- 0.087 vs. 0.525 +/- 0.039, g/g x 100, P < 0.05), which was prevented by losartan (0.506 +/- 0.069, g/g x 100, P < 0.0001) despite similar hemodynamic load (proximal systolic pressure 146 +/- 31 vs. 136 +/- 32 mmHg, untreated vs. losartan, P = NS). Proximal systolic pressure was positively correlated with the development of ventricular hypertrophy. In the presence of AT1-receptor blockade, the increase in heart weight-to-body weight ratio at any given systolic pressure was significantly attenuated compared with untreated TAC mice. The increase in heart weight-to-body weight ratio was also significantly attenuated by captopril compared with untreated banded controls (0.542 +/- 0.091, g/g x 100, P = 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
越来越多的证据表明,肾素-血管紧张素系统可能在心脏肥大中起重要作用。为了评估血管紧张素II在诱导心脏肥大中的作用,三组成年小鼠通过横向主动脉缩窄(TAC)使其左心室压力过载。在接下来的7天里,这些组分别在饮用水中给予特异性血管紧张素II 1型受体(AT1)拮抗剂(氯沙坦,1.05 g/l;n = 17)、血管紧张素酶抑制剂(卡托普利,2 g/l;n = 17)或不进行处理(n = 22),并与三个经过类似处理的假手术组(每组n = 7)进行比较。TAC导致心脏重量与体重之比显著增加(0.634±0.087对0.525±0.039,g/g×100,P < 0.05),尽管血流动力学负荷相似(近端收缩压146±31对136±32 mmHg,未处理对氯沙坦,P = 无显著性差异),但氯沙坦可防止这种增加(0.506±0.069,g/g×100,P < 0.0001)。近端收缩压与心室肥大的发展呈正相关。在存在AT1受体阻断的情况下,与未处理的TAC小鼠相比,在任何给定收缩压下心脏重量与体重之比的增加均显著减弱。与未处理的结扎对照组相比,卡托普利也显著减弱了心脏重量与体重之比的增加(0.542±0.091,g/g×100,P = 0.01)。(摘要截短于250字)